Tech Company Financing Transactions
Zogenix Funding Round
Zogenix, based in Emeryville, scored $10 million from GE Commercial Finance.
Transaction Overview
Company Name
Announced On
3/19/2007
Transaction Type
Debt
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Zogenix will use the loan to finance the launch of its first product, sumatriptan Intraject®, for the acute treatment of migraines.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
5858 Horton St. 455
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Website
Email Address
Overview
Zogenix (NASDAQ: ZGNX) is a specialty pharmaceutical company whose goal is to uniquely enhance and differentiate medicines by incorporating innovative technologies in an effort to relieve suffering in people with CNS and pain disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Farr
Chief Financial Officer
Michael Smith
Chief Medical Officer
Bradley Galer
VP - Bus. Development
Gail Farfel
VP - Bus. Development
Ashish Sagrolikar
Browse more venture capital transactions:
Prev: 3/19/2007: Intarcia Therapeutics venture capital transaction
Next: 3/19/2007: NeuroPure venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs